Pharmaceutical Technology

JUNE 9, 2023

Novaliq medical science and regulatory affairs vice-president Sonja Krösser stated: “We are proud that the FDA approved VEVYE. The safety and efficacy of VEVYE were assessed in a total of 1,369 patients with dry eye disease, of which 738 received VEVYE. “It

Food and Drug Administration 98

Food and Drug Administration FDA Medical science Food 98

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 28, 2023

These efficacy results, combined with the safety profile that allows patients to complete their treatment regimen, are extremely encouraging. Can you share some highlights from the data presented at ASH 2023? The IND for the combination was cleared in May 2023 and we have now treated patients in the first two cohorts.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

European Pharmaceutical Review

MAY 2, 2023

By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4].

Patients 105

Patients Medicine Marketing Medical 105

PM360

MARCH 22, 2024

Field Medical Affairs is an essential bridge between pharmaceutical clinical development and commercial delivery. Historically, the industry has left MSL-HCP interactions to exist on their own, focusing on objective metrics and key performance indicators (KPIs) to inform Medical Affairs impact. October 2023. EPG Health.

Medical 52

Medical Education Sales Medical science 52

European Pharmaceutical Review

AUGUST 15, 2024

Second generation BTKi, acalabrutinib, was designed to be more specific against the target to mitigate some of the toxicities associated with ibrutinib and has demonstrated an improved safety profile in head-to-head clinical trial ELEVATE-RR (acalabrutinib vs ibrutinib) but with similar efficacy (non-inferiority trial with hazard ratio (HR)=1.0).

Safety 52

Safety Patients Medical Medicine 52

Medgadget

MARCH 2, 2023

Moreover, due to the different nature of healthy and cancerous tissue, alpha radiation produced by Alpha DaRT sources diffuses about a millimeter into healthy tissue while penetrating at a diameter up to about five millimeters into tumors, providing an automatic safety mechanism. More info can be found at the Biomed Israel website.

Manufacturing 82

Manufacturing Leads Patients Medicine 82